Author of

• 16549

  +

  P1.02 - Poster Session with Presenters Present (ID 454)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Biology/Pathology
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 16553

    +

    P1.02-004 - A Retrospective Analysis of Frequency of ALK Gene Rearrangement in Saudi Lung Patients (ID 3858)

    14:30 - 14:30  |  Author(s): H. Al Husaini
    • Abstract
    • Slides

    Background:
    Lung carcinoma represents 2.9% of cancers seen at King Faisal Specialist Hospital and Research Centre (KFSH&RC) as per KFSH&RC Tumor Registry (2013), and 4% of cancers in Saudi Arabia as per National Cancer Registry (2010). EML4-ALK re-arrangement play an important oncogenic driver role in lung adenocarcinoma tumorgenesis in 3-5% of cases. ALK gene rearrangement (inversion in chromosome 2) testing can identify patients with adenocarcinoma who are sensitive to ALK tyrosine kinase inhibitors. No data is available on the prevalence of ALK rearrangement changes in Saudi lung cancer patients. The aim of this study is to evaluate the prevalence of ALK gene rearrangement in lung adenocarcinoma of Saudi patients.
    
    Methods:
    A total of 172 cases of lung adenocarcinoma diagnosed at KFSH&RC between January 2013 to May 2016 were identified. Formalin-fixed paraffin embedded tissue samples of these patients were analyzed for ALK gene rearrangement using fluorescence in situ hybridization (FISH), utilizing break-apart probes from Vysis (Abott Molecular, II, USA).
    
    Results:
    Eleven (11) cases exhibited ALK gene rearrangement (6.4%). Nine out of eleven cases were stage IV and two cases were stage III. Median patients age was 47 years (21-71 year) with male predominance (males 77%, female 25%). All cases were moderately to poorly differentiated adenocarcinoma. None of our cases showed signet ring cells or abundant intracellular mucin.
    
    Conclusion:
    Our findings showed the incidence of ALK gene rearrangement in lung adenocarcinoma in Saudi patients is 6.4%. This is slightly higher in comparison to the published data which may be attributed to KFSH&RC being a tertiary referral Center.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.